210 related articles for article (PubMed ID: 24520381)
1. Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers.
Schleifman EB; Desai R; Spoerke JM; Xiao Y; Wong C; Abbas I; O'Brien C; Patel R; Sumiyoshi T; Fu L; Tam RN; Koeppen H; Wilson TR; Raja R; Hampton GM; Lackner MR
PLoS One; 2014; 9(2):e88401. PubMed ID: 24520381
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
3. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
Esteva FJ; Guo H; Zhang S; Santa-Maria C; Stone S; Lanchbury JS; Sahin AA; Hortobagyi GN; Yu D
Am J Pathol; 2010 Oct; 177(4):1647-56. PubMed ID: 20813970
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
5. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.
Creighton CJ; Fu X; Hennessy BT; Casa AJ; Zhang Y; Gonzalez-Angulo AM; Lluch A; Gray JW; Brown PH; Hilsenbeck SG; Osborne CK; Mills GB; Lee AV; Schiff R
Breast Cancer Res; 2010; 12(3):R40. PubMed ID: 20569503
[TBL] [Abstract][Full Text] [Related]
6. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
7. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
Chandarlapaty S; Sakr RA; Giri D; Patil S; Heguy A; Morrow M; Modi S; Norton L; Rosen N; Hudis C; King TA
Clin Cancer Res; 2012 Dec; 18(24):6784-91. PubMed ID: 23092874
[TBL] [Abstract][Full Text] [Related]
8. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
Gonzalez-Angulo AM; Ferrer-Lozano J; Stemke-Hale K; Sahin A; Liu S; Barrera JA; Burgues O; Lluch AM; Chen H; Hortobagyi GN; Mills GB; Meric-Bernstam F
Mol Cancer Ther; 2011 Jun; 10(6):1093-101. PubMed ID: 21490305
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
[TBL] [Abstract][Full Text] [Related]
10. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
[TBL] [Abstract][Full Text] [Related]
11. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.
Ellis MJ; Lin L; Crowder R; Tao Y; Hoog J; Snider J; Davies S; DeSchryver K; Evans DB; Steinseifer J; Bandaru R; Liu W; Gardner H; Semiglazov V; Watson M; Hunt K; Olson J; Baselga J
Breast Cancer Res Treat; 2010 Jan; 119(2):379-90. PubMed ID: 19844788
[TBL] [Abstract][Full Text] [Related]
13. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer.
Dupont Jensen J; Laenkholm AV; Knoop A; Ewertz M; Bandaru R; Liu W; Hackl W; Barrett JC; Gardner H
Clin Cancer Res; 2011 Feb; 17(4):667-77. PubMed ID: 20940279
[TBL] [Abstract][Full Text] [Related]
15. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Stemke-Hale K; Gonzalez-Angulo AM; Lluch A; Neve RM; Kuo WL; Davies M; Carey M; Hu Z; Guan Y; Sahin A; Symmans WF; Pusztai L; Nolden LK; Horlings H; Berns K; Hung MC; van de Vijver MJ; Valero V; Gray JW; Bernards R; Mills GB; Hennessy BT
Cancer Res; 2008 Aug; 68(15):6084-91. PubMed ID: 18676830
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting.
Adamczyk A; Niemiec J; Janecka A; Harazin-Lechowska A; Ambicka A; Grela-Wojewoda A; Domagała-Haduch M; Cedrych I; Majchrzyk K; Kruczak A; Ryś J; Jakubowicz J
Pol J Pathol; 2015 Jun; 66(2):133-41. PubMed ID: 26247526
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
Loi S; Michiels S; Baselga J; Bartlett JM; Singhal SK; Sabine VS; Sims AH; Sahmoud T; Dixon JM; Piccart MJ; Sotiriou C
PLoS One; 2013; 8(1):e53292. PubMed ID: 23301057
[TBL] [Abstract][Full Text] [Related]
18. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.
Fedele CG; Ooms LM; Ho M; Vieusseux J; O'Toole SA; Millar EK; Lopez-Knowles E; Sriratana A; Gurung R; Baglietto L; Giles GG; Bailey CG; Rasko JE; Shields BJ; Price JT; Majerus PW; Sutherland RL; Tiganis T; McLean CA; Mitchell CA
Proc Natl Acad Sci U S A; 2010 Dec; 107(51):22231-6. PubMed ID: 21127264
[TBL] [Abstract][Full Text] [Related]
19. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S
Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706
[TBL] [Abstract][Full Text] [Related]
20. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Chen L; Yang L; Yao L; Kuang XY; Zuo WJ; Li S; Qiao F; Liu YR; Cao ZG; Zhou SL; Zhou XY; Yang WT; Shi JX; Huang W; Hu X; Shao ZM
Nat Commun; 2018 Apr; 9(1):1357. PubMed ID: 29636477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]